The FDA decision on Travere Therapeutics Inc.’s (TVTX) New Drug Application seeking accelerated approval of Sparsentan for the treatment of IgA nephropathy is due on February 17, 2023.IgA nephropathy, also called Berger’s disease, is a rare kidney disorder characterized by the build-up of the protein immunoglobulin A (IgA) in the kidneys. The accumulation of IgA hinders the normal filtering mechanisms in the kidney, leading to blood in the urine (hematuria), and protein in the urine (proteinuria).Sparsentan is a Dual Endothelin Angiotensin Receptor Antagonist (DEARA) that selectively targets the endothelin A receptor (ET A R) and the angiotensin II subtype 1 receptor (AT 1 R). This compound is designed to sustainably reduce proteinuria and protect the long-term health of kidneys in people living with IgA nephropathy.If approved, Sparsentan will have to compete with Calliditas Therapeutics’ (CALT) Tarpeyo, the first and only FDA approved treatment for IgA nephropathy. Tarpeyo was launched in the U.S. last January and the total net sales of the drug in 2022 is estimated to be in the range of $35 million to $40 million.TVTX closed Friday’s trading at $21.88, up 0.23%.